ARID1A and cancer: ARID1A-deficient cells are also sensitive to ATR inhibitors (ATRi), which have potential for cancer therapy in the near future (Shen et al., 2015; Williamson et al., 2016; Yazinski and Zou, 2016; Hopkins et al., 2022).